Jakafi
Jakafi | |
---|---|
Term | Jakafi |
Short definition | Jakafi (JA-kah-fy) A drug used to treat adults with certain types of primary myelofibrosis (MF), post-polycythemia vera MF, post-essential thrombocythemia MF, or polycythemia vera, and adults and Children 12 years and older with acute or chronic graft-versus-host disease. It is also being studied in the treatment of some types of cancer. |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
Jakafi - (pronounced) (JA-kah-fy) A drug used to treat adults with certain types of primary myelofibrosis (MF), post-polycythemia vera MF, post-essential thrombocythemia MF, or polycythemia vera, and adults and Children 12 years and older with acute or chronic graft-versus-host disease. It is also being studied in the treatment of some types of cancer. Jakafi blocks a protein called JAK, which can help prevent abnormal blood cells or cancer cells from growing. It can also decrease the body's immune response. Jakafi is a type of tyrosine kinase inhibitor. Also called ruxolitinib phosphate
External links
- Medical encyclopedia article on Jakafi
- Wikipedia's article - Jakafi
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski